3rd International Conference on Chemo and BioInformatics, Kragujevac, September 25-26. 2025. (pp. 273-275)
АУТОР(И) / AUTHOR(S): Aleksandra Nikolić, Jelena Karanović
Download Full Pdf 
DOI: 10.46793/ICCBIKG25.273N
САЖЕТАК / ABSTRACT:
Colon adenocarcinoma (COAD) is the third most prevalent cancer and the second leading cause of cancer-related mortality worldwide. Among epigenetic regulatory mechanisms, adenosine-to-inosine (A-to-I) RNA editing, mediated by ADAR enzymes, plays a crucial role in the diversification of transcriptomic and proteomic processes. Dysregulated ADAR and ADARB1 activity has been associated with both oncogenic and tumor suppressor functions in various cancers, though their role in COAD remains insufficiently characterized. Recent findings highlight the diagnostic potential of non-coding RNAs derived from protein-coding genes. This study aimed to identify ADARB1 non-coding transcriptomic biomarkers in COAD through publicly available expression data and in silico analyses. From 15 ADARB1 transcripts, nine were selected based on differential expression between tumor and normal colon tissue. Of these, four (ADARB1-207, ADARB1-208, ADARB1-209, and ADARB1-210) were predicted to be non-coding. Subcellular localization analysis suggested nuclear enrichment for ADARB1-207, cytoplasmic distribution for ADARB1-208 and ADARB1-210, and potential exosomal association for ADARB1-209. These findings provide an initial insight into the biomarker potential of ADARB1 non-coding RNAs in COAD and form a foundation for future experimental validation and functional studies.
КЉУЧНЕ РЕЧИ / KEYWORDS:
colon adenocarcinoma, RNA editing, ADARB1, transcripts, non-coding biomarkers
ПРОЈЕКАТ / ACKNOWLEDGEMENT:
This research is funded by the Ministry of Education and the Ministry of Science, Technological Development and Innovation, Republic of Serbia, Grants: No. 451-03- 136/2025-03/200042.
ЛИТЕРАТУРА / REFERENCES:
- F. Bray, M. Laversanne, H. Sung, J. Ferlay, R.L. Siegel, I. Soerjomataram, A. Jemal., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: A Cancer Journal for Clinicians, 74 (2024) 229–263.
- K. Nishikura., A-to-I editing of coding and non-coding RNAs by ADARs, Nature Reviews Molecular Cell Biology, 17 (2016) 83–96.
- L. Chen, Y. Li, C.H. Lin, T.H.M. Chan, R.K.K. Chow, Y. Song, M. Liu, Y.F. Yuan, L. Fu, K.L. Kong, L. Qi, Y. Li, N. Zhang, A.H.Y. Tong, D.L.W. Kwong, K. Man, C.M. Lo, S. Lok, D.G. Tenen, X.Y. Guan., Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma, Nature Medicine, 19 (2013) 209–216.
- K. Fritzell, L.D. Xu, J. Lagergren, M. Öhman., ADARs and editing: The role of A-to-I RNA modification in cancer progression, Seminars in Cell & Developmental Biology, 79 (2018) 123–130.
- A. F. Palazzo, E.S. Lee., Non-coding RNA: what is functional and what is junk?, Frontiers in Genetics, 6 (2015) 2.